YHYuko Hirao

Yuko Hirao

*This is an algorithmically generated author record based on publicly available information.

Yuko Hirao has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of Low‐Voltage Area Ablation Across Substrate Size in Persistent Atrial Fibrillation: A Post Hoc Analysis of the SUPPRESS‐AF Randomized Trial

    by Masato Okada, Daisuke Sakamoto, Masaharu Masuda, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, Tomoko Minamisaka, Masato Kawasaki, et al.

    Background: Larger low‐voltage areas (LVAs) in the left atrium are associated with increased arrhythmia recurrence after atrial fibrillation (AF) ablation. The benefit of adjunctive LVA ablation may therefore depend on substrate extent. This study examined the efficacy of LVA ablation across a spectrum of LVA sizes in persistent AF. Methods: The SUPPRESS‐AF (Efficacy and Safety of Left Atrial Low‐Voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation) trial screened 1364 patients undergoing initial ablation for persistent AF, of whom 342 with left atrial LVAs (≥5 cm 2 ) were randomized to pulmonary vein isolation with or without adjunctive LVA ablation. In the 341 analyzed patients, LVA size was categorized as small (2 , n=106), moderate (≥10 to 2 , n=127), or extensive (≥20 cm 2 , n=108). The primary end point was recurrence of AF or atrial tachycardia within 1 year without antiarrhythmic drugs. Treatment effects across LVA sizes were evaluated using a Cox model with restricted cubic splines. Results: AF/atrial tachycardia recurrence rates were similar between the pulmonary vein isolation+LVA ablation and pulmonary vein isolation‐alone groups in patients with small (38.5% versus 29.6%; P =0.28) and moderate LVA sizes (40.6% versus 53.5%; P =0.15). However, adjunctive LVA ablation significantly reduced recurrence in patients with extensive LVAs (34.7% versus 57.6%; P =0.029; interaction P =0.054), driven mainly by lower AF recurrence (18.4% versus 42.4%, P =0.008). Spline analysis indicated a greater treatment benefit with increasing LVA size, reaching significance around 20 cm 2 . Conclusions: The efficacy of adjunctive LVA ablation increased with substrate size, with a significant benefit observed in patients with extensive LVAs. These findings support a substrate size–guided ablation strategy to optimize rhythm outcomes in persistent AF. Registration: URL: https://www.umin.ac.jp/ctr ; Identifier: UMIN000035940.


  • Open Access

    Clinical Implications of Left Atrial and Ventricular Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Systolic Dysfunction

    by Masato Okada, Nobuaki Tanaka, Yasushi Koyama, Koji Tanaka, Yuko Hirao, Naoko Miyazaki, Kohei Iwasa, Heitaro Watanabe, Yoshitaka Iwanaga, Atsunori Okamura, et al.

    Background: Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods: Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction P P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions: LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.


  • Open Access

    Prognostic Implications of Heart Rate Score and Its Temporal Change in Left Ventricular Systolic Dysfunction: Insights From the HINODE Study

    by Masato Okada, Koichi Inoue, Nobuaki Tanaka, Koji Tanaka, Yuko Hirao, Torri Schwartz, Torsten Kayser, Akihiko Nogami, Takeshi Mitsuhashi, Toyoaki Murohara, et al.

    Background: Heart rate score (HrSc) ≥ 70% reflects chronotropic incompetence and predicts prognosis in patients with cardiac implantable electronic devices (CIEDs) and left ventricular (LV) systolic dysfunction. However, its prognostic value in Japanese patients remains underexplored, and longitudinal changes in HrSc and their contributing factors are poorly characterized. Methods: This post hoc analysis of the Heart Failure Indication and Sudden Cardiac Death Prevention Trial in Japan (HINODE) included 172 patients with CIEDs and LV ejection fraction ≤ 50%. HrSc, defined as the percentage of all atrial‐paced and sensed beats in a single tallest 10 beat/min device histogram bin, was assessed using remote monitoring. Results: At baseline, the median HrSc was 53% (interquartile range, 41%–83%), with 68 (39.5%) patients having HrSc ≥ 70%. During the 2‐year follow‐up, the incidence of all‐cause death or heart failure (HF) events was similar between patients with HrSc ≥ 70% and < 70% (31.1% vs. 29.4%, log‐rank p = 0.862). However, among 142 patients whose follow‐up data were available, HrSc increased from < 70% to ≥ 70% in 13 patients (13%) and decreased from ≥ 70% to < 70% in 19 (9.1%). An increase in HrSc was associated with lower LV ejection fraction, antiarrhythmic drug initiation, increased lower rate limit, and HF events. Conclusion: In the HINODE study, baseline HrSc ≥ 70% was not predictive of 2‐year cardiovascular outcomes. However, HrSc changed in approximately one‐quarter of patients and was associated with clinical and device‐related factors, as well as HF events. HrSc is not a static measure but a dynamic marker that reflects evolving patient conditions and CIED programming.

  • Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation

    by Masato Okada, Koichi Inoue, Nobuaki Tanaka, Masaharu Masuda, Tetsuya Watanabe, Nobuhiko Makino, Yasuyuki Egami, Takafumi Oka, Hitoshi Minamiguchi, Miwa Miyoshi, et al.

    BACKGROUND: The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03514693 ). METHODS: The EARNEST-PVI trial is a randomized controlled study evaluating index ablation strategies for persistent AF. Of the 512 trial participants, 115 who underwent redo AF ablation (pulmonary vein isolation [PVI]-alone redo [n=69] and PVI-plus linear redo [n=46]) were included in the present study. Left atrial conduction gaps, the occurrence of left atrial tachycardias during redo procedures, and subsequent recurrences were compared between the PVI-alone redo group and the PVI-plus linear ablation redo group. RESULTS: In the PVI-alone redo group, electrical PV gaps were observed in 38 (57%) patients. In the PVI-plus redo group, 19 (41%) had PV gaps, 10 (22%) had gaps in left atrial linear lines, and 11 (24%) had gaps in both. During the redo session, 19 left atrial tachycardias were observed or induced in 15 patients. Atrial tachycardias were more frequently observed in the PVI-plus group than in the PVI-alone group (23.9% versus 5.8%; P =0.005). The occurrence of left atrial tachycardias was associated with gaps in linear lesions, whereas PV gaps alone were associated with subsequent recurrence after redo (hazard ratio, 0.54 [95% CI, 0.31–0.95]; P =0.033). CONCLUSIONS: In the redo AF ablation of the EARNEST-PVI trial, left atrial conduction gaps were more frequent in patients who underwent extensive linear ablation during the index procedure. While all gaps during redo were potentially arrhythmogenic, PV gaps alone were associated with recurrence after redo AF ablation. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index-j.htm ; Unique identifier: UMIN000019449.


  • Open Access

    Impact of Long‐Term CPAP Adherence on Recurrence After Atrial Fibrillation Ablation in Patients With Severe Sleep Apnea

    by Nobuaki Tanaka, Masato Okada, Koji Tanaka, Yuko Hirao, Naoko Miyazaki, Kohei Iwasa, Yasushi Koyama, Yoshitaka Iwanaga, Heitaro Watanabe, Kenshi Fujii, et al.

    Background: Obstructive sleep apnea represents an arrhythmia recurrence risk following catheter ablation of atrial fibrillation (AF). Continuous positive airway pressure (CPAP) therapy may reduce recurrence, but individual adherence to CPAP varies, potentially leading to inconsistent results across studies. Methods and Results: We analyzed the impact of CPAP adherence on AF recurrence after catheter ablation in patients with severe obstructive sleep apnea (apnea‐hypopnea index ≥30). Of 1864 consecutive patients undergoing an index catheter ablation of AF, those with severe obstructive sleep apnea were enrolled in this study. Recurrence rates were compared between patients with and without long‐term CPAP adherence (>1‐year use). CPAP use was monitored via telemonitoring and outpatient follow‐ups. Among 466 patients, 157 (33.7%) adhered to CPAP long‐term, reducing apnea‐hypopnea index from 37.7±15.3 to 3.9±3.1 ( P P =0.0002). Even after adjusting for potential confounders, long‐term CPAP treatment was associated with a lower risk of very late recurrence (adjusted hazard ratio, 0.30 [95% CI, 0.14–0.57]). Conclusions: In patients with severe obstructive sleep apnea at baseline, AF recurrence rates within 1‐year postablation were similar regardless of CPAP adherence. However, long‐term CPAP therapy was associated with a reduced AF recurrence rate in the subsequent period.


  • Open Access

    Impact of left atrial appendage flow velocity on thrombus resolution and clinical outcomes in patients with atrial fibrillation and silent left atrial thrombi: insights from the LAT study

    by Masato Okada, Koichi Inoue, Nobuaki Tanaka, Koji Tanaka, Yuko Hirao, Katsuomi Iwakura, Yasuyuki Egami, Masaharu Masuda, Tetsuya Watanabe, Hitoshi Minamiguchi, et al.

    Aims: Blood stasis is crucial in developing left atrial (LA) thrombi. LA appendage peak flow velocity (LAAFV) is a quantitative parameter for estimating thromboembolic risk. However, its impact on LA thrombus resolution and clinical outcomes remains unclear. Methods and results: The LAT study was a multicentre observational study investigating patients with atrial fibrillation (AF) and silent LA thrombi detected by transoesophageal echocardiography (TEE). Among 17 436 TEE procedures for patients with AF, 297 patients (1.7%) had silent LA thrombi. Excluding patients without follow-up examinations, we enrolled 169 whose baseline LAAFV was available. Oral anticoagulation use increased from 85.7% at baseline to 97.0% at the final follow-up (P < 0.001). During 1 year, LA thrombus resolution was confirmed in 130 (76.9%) patients within 76 (34–138) days. Conversely, 26 had residual LA thrombi, 8 had thromboembolisms, and 5 required surgical removal. These patients with failed thrombus resolution had lower baseline LAAFV than those with successful resolution (18.0 [15.8–22.0] vs. 22.2 [17.0–35.0], P = 0.003). Despite limited predictive power (area under the curve, 0.659; P = 0.001), LAAFV ≤ 20.0 cm/s (best cut-off) significantly predicted failed LA thrombus resolution, even after adjusting for potential confounders (odds ratio, 2.72; 95% confidence interval, 1.22–6.09; P = 0.015). The incidence of adverse outcomes including ischaemic stroke/systemic embolism, major bleeding, or all-cause death was significantly higher in patients with reduced LAAFV than in those with preserved LAAFV (28.4% vs. 11.6%, log-rank P = 0.005). Conclusion: Failed LA thrombus resolution was not rare in patients with AF and silent LA thrombi. Reduced LAAFV was associated with failed LA thrombus resolution and adverse clinical outcomes.